AzTrials
AzTrials

Diabetes Mellitus (Type 2)ARISENCT07846319

Evaluation of the Effectiveness of Implementing a Screening Strategy for the Diagnosis of Prediabetes and Type 2 Diabetes Mellitus in Primary Health Care in a Brazilian Municipality

A study testing ARISE Strategy in people with Diabetes Mellitus (Type 2) and Prediabetes, run by epHealth at 2 sites in Brazil.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Primary objective: To evaluate the effectiveness of the ARISE strategy on the proportion of individuals with confirmed T2DM diagnosis, per protocol criteria based on the PCDT-DM2 (Clinical Protocol and Therapeutic Guidelines for T2DM), among adults eligible for screening registered at UBS (Primary Health Care Units)… Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Diabetes Mellitus (Type 2), Prediabetes
What is being tested?
ARISE Strategy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
45,000 participants
Where
2 sitesBrazil
Study dates
Nov 2026to Nov 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • POPULATION FOR CARE-RELATED DATA: The population will consist of adults registered with municipal Primary Health Care who meet the eligibility criteria for T2DM screening on the index date of each period. In general, the following will be considered potentially eligible: (i) individuals aged 35 years or older; (ii) individuals aged 18 to 34 years with overweight or obesity and at least one risk factor defined in the protocol; (iii) individuals aged 18 years or older presenting certain high-risk conditions. Factors and conditions assessed include cardiovascular disease, dyslipidemia, arterial hypertension, prior laboratory-confirmed prediabetes, prior gestational diabetes, current pregnancy, antipsychotic use, obstructive sleep apnea syndrome, HIV/AIDS, cystic fibrosis, and history of transplantation.
  • HEALTHCARE PROFESSIONAL PARTICIPANTS: Professionals will be considered research participants exclusively for the components evaluating educational impact, acceptability, and usability of the strategy. Eligible professionals will be those aged 18 years or older, currently working in the municipality, directly involved in the implementation or operationalization of the strategy, who attend the training corresponding to their role and agree by signing the Informed Consent Form (ICF). Participation in institutional training will not be contingent on participation in the research. Refusal to authorize the use of questionnaire data will not result in any functional, hierarchical, or institutional penalty.

Who cannot join

  • POPULATION FOR CARE-RELATED DATA: Individuals with prior evidence of diabetes or with recent screening will be excluded, according to the windows and rules defined in the protocol. Criteria were limited to information that could be reliably identified in the structured fields of available data sources. The absence of a record of a given condition will not be interpreted as confirmation of its absence.
  • HEALTHCARE PROFESSIONAL PARTICIPANTS: Professionals absent from training sessions due to vacation, leave, medical leave, or any other reason will not be included in the research components related to healthcare professionals.

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Leonardo A Carbonera, PhD contact

48 936182615 ext. +55

leonardo@ephealth.com.br

Brazil2 sites
  • Municipal Health Secretariat of Afogados da Ingazeira

    Afogados da Ingazeira, Pernambuco, 56800-000

    Pedro M Pereira, 48 936182615 ext. +55, pedro@ephealth.com.br

    Gabriela M Silva, RN, 48 936182615 ext. +55, gabriela@ephealth.com.br

  • epHealth

    Florianópolis, Santa Catarina, 88032-005

    Pedro M Pereira, 48 936182615 ext. +55, pedro@ephealth.com.br

    Gabriela M Silva, RN, 48 936182615 ext. +55, gabriela@ephealth.com.br

Other trials in Brazil

About this study

Official title: Single-arm Intervention Study With Historical Comparator to Evaluate the Effectiveness of Implementing a Screening Strategy for the Diagnosis of Prediabetes and Type 2 Diabetes Mellitus in Primary Health Care in a Brazilian Municipality

Primary objective: To evaluate the effectiveness of the ARISE strategy on the proportion of individuals with confirmed T2DM diagnosis, per protocol criteria based on the PCDT-DM2 (Clinical Protocol and Therapeutic Guidelines for T2DM), among adults eligible for screening registered at UBS (Primary Health Care Units) in Afogados da Ingazeira, during the 12 months post-implementation, compared to a reference value estimated from a historical 12-month period in the same municipality.

Methodology: Pragmatic, quasi-experimental, single-arm effectiveness and implementation study with a historical comparator. In each period, the analytic population will be defined by eligibility on the respective index date. In the historical period, data will estimate the reference proportion of the primary outcome and historical values of applicable secondary outcomes. In the post-intervention period, individuals eligible on the index date will be followed for 12 months via care records. Individuals who become eligible after the post-intervention index date may receive care actions under the strategy and be included in operational, implementation, and exploratory analyses, but not in outcome denominators fixed at the index date.

Read more

The study will take place in Afogados da Ingazeira, Pernambuco, covering all 15 UBS with an affiliated Family Health Team. Research-specific technological components will incur no additional cost to the municipality.

ARISE comprises two components:

  1. Digital analytics layer, built on the existing epHealth infrastructure. It uses structured data from e-SUS PEC to apply predefined T2DM screening eligibility rules. Identified individuals appear in operational lists and may generate alerts for UBS managers and community health workers, supporting visits, scheduling, test requests, follow-up, and patient return. It may also flag: delays over 60 days between test request and completion, availability of lab results, and need for active case-finding. No test, diagnosis, prescription, referral, or treatment is automated; clinical decisions remain with APS professionals and managers.
  2. Professional training. UBS managers, community health workers, physicians, nurses, and nursing technicians will be trained on the PCDT-DM2 and ARISE workflows, before the digital layer's activation. Professionals are research participants only for evaluating educational impact, acceptability, and usability, provided they attend the relevant training and sign the Informed Consent Form (ICF). Training participation is independent of research participation; declining data use carries no functional or institutional penalty.

A census-based approach will define population size. The primary analysis includes all individuals eligible on the post-intervention index date; final numbers depend on municipal database findings. Power calculations covered 8,000-30,000 eligible individuals and historical T2DM diagnosis proportions of 0.80%-0.90%. A population of ~14,000-15,000 eligible individuals yields ~80% power to detect a ~25% relative increase, for historical proportions of 0.85%-0.90%. For professional-related components, a census approach covers all eligible categories per the updated roster of active professionals directly involved.

Statistical analysis: The post-intervention proportion of confirmed T2DM diagnosis will be compared to the historical reference using a two-tailed one-proportion test (5% significance level). Point estimates, 95% CIs, absolute differences, and proportion ratios (where applicable) will be reported. Adjusted analyses may use logistic regression. Change in professionals' knowledge will be analyzed via paired intra-individual pre/post-training score differences. RE-AIM indicators will be mainly descriptive. Acceptability, training reaction, and workflow perception blocks will be scored separately (1-5). Usability will be assessed via the System Usability Scale (0-100) among professionals who directly used the digital component.

The study was approved by the Research Ethics Committee (REC), CAAE n. 00260026.5.0000.5330, approval opinion n. 8.705.723.

Primary outcome: Confirmed T2DM diagnosis during the observation period, treated as a binary individual indicator.

Read the detailed description

Background: Type 2 diabetes mellitus (T2DM) is a major cause of morbidity, disability, and premature mortality. A significant proportion of people with T2DM remain undiagnosed, and prediabetes is even less frequently identified. Although Primary Health Care has guidelines for screening, systematic identification of eligible individuals is hindered by data fragmentation, incomplete records, interoperability limitations, and the absence of mechanisms to operationalize the criteria of the Clinical Protocol and Therapeutic Guidelines for T2DM in teams' routine practice.

Primary objective: To evaluate the effectiveness of the ARISE strategy on the proportion of individuals with confirmed T2DM diagnosis, according to the criteria defined in the protocol and based on the PCDT-DM2 (Clinical Protocol and Therapeutic Guidelines for T2DM), among adults eligible for screening registered at the UBS (Primary Health Care Units) of Afogados da Ingazeira, during the 12 months following implementation, compared to a reference value estimated from a historical 12-month period in the same municipality.

Methodology: This is a pragmatic, quasi-experimental, single-arm effectiveness and implementation study using a historical comparator. The following periods will be defined: a historical reference period, lasting 12 months; a preparation and implementation period, lasting up to 30 days; and a post-intervention period, lasting 12 months, beginning on the activation date of the digital analytics layer. In each period, the analytic population will be defined based on eligibility existing on the respective index date. In the historical period, data will be used to estimate the reference proportion of the primary outcome and the historical values of applicable secondary outcomes. In the post-intervention period, individuals eligible on the index date will be followed for 12 months through care records. Individuals who become eligible after the post-intervention index date may receive the care actions provided for in the strategy and be included in operational, implementation, and exploratory analyses, but will not be included in the denominators of outcomes whose population was fixed at the index date.

The study will be conducted in the municipality of Afogados da Ingazeira, Pernambuco, including the 15 Primary Health Care Units (UBS) with an affiliated Family Health Team. The municipality has an estimated population of 40,241 inhabitants and has used epHealth digital solutions integrated into Primary Health Care routine since 2018. The municipality's participation will be voluntary and formalized through a Technical Cooperation Agreement, which will establish the parties' responsibilities, the conditions for data access and processing, and the integration of the strategy into the municipal care routine. Implementation of the research-specific technological components will not incur any additional cost to the municipality.

The ARISE strategy will consist of two components:

  1. Digital analytics layer. This will be configured on top of the epHealth infrastructure already deployed in the municipality. The layer will use structured data extracted from the e-SUS PEC (Primary Care Information System) to apply predefined eligibility rules for T2DM screening. Identified individuals will be made available in operational lists and may generate alerts for UBS managers, community health workers, and community health worker technicians. The alerts will support the organization of visits, contacts, scheduling, test requests, follow-up of pending items, and patients' return to the unit. The layer may also flag: delays exceeding 60 days between test request and completion; availability of laboratory results; and the need to organize active case-finding. Alerts will be issued during business hours and will not display laboratory result values. No test, consultation, diagnosis, prescription, referral, or treatment will be carried out automatically. Clinical decision-making will remain the responsibility of primary care professionals and managers.
  2. Professional training. UBS managers, community health workers, community health worker technicians, physicians, nurses, and nursing technicians will receive training on the Clinical Protocol and Therapeutic Guidelines for T2DM (PCDT-DM2) and on the operational workflows of the ARISE strategy. Training will be conducted prior to activation of the digital analytics layer. Professionals will be considered research participants exclusively for the components evaluating educational impact, acceptability, and usability of the strategy. Eligible professionals will be those aged 18 years or older, currently working in the municipality, directly involved in the implementation or operationalization of the strategy, who attend the training corresponding to their role and agree by signing the Informed Consent Form (ICF). Participation in institutional training will not be contingent on participation in the research. Refusal to authorize the use of questionnaire data will not result in any functional, hierarchical, or institutional penalty.

A census-based approach will be used for population size. The primary analysis will include all individuals meeting eligibility criteria on the post-intervention index date. The final number will depend on the population actually identified as eligible in the municipal databases. Power calculations considered scenarios ranging from 8,000 to 30,000 eligible individuals and historical proportions of confirmed T2DM diagnosis between 0.80% and 0.90%. A population of approximately 14,000 to 15,000 eligible individuals provides power close to 80% to detect a relative increase of approximately 25%, in scenarios with a historical proportion between 0.85% and 0.90%. For the components involving professionals, a census-based approach will be used across eligible categories and roles, according to the updated list of professionals in active service who are directly involved in the strategy.

For the statistical analysis, the proportion of confirmed T2DM diagnosis observed in the post-intervention period will be compared to the historical reference proportion using a two-tailed one-proportion test, considering a 5% significance level. Point estimates, 95% confidence intervals, absolute differences, and, where applicable, proportion ratios will be presented. Adjusted analyses and assessments of associated factors may use logistic regression models. Change in professionals' knowledge will be analyzed in a paired manner, using the intra-individual difference between post- and pre-training scores. RE-AIM indicators will be evaluated predominantly in a descriptive manner. The blocks assessing acceptability, reaction to training, and perception of workflow will be analyzed separately, using scores from 1 to 5. Usability will be assessed using the System Usability Scale, with scores from 0 to 100, among professionals who directly used the digital component.

The intervention will last 12 months, preceded by a preparation and training period of up to 30 days. The historical reference period will also comprise 12 months. After the end of the post-intervention period, database consolidation, statistical analyses, report preparation, and scientific dissemination of results will be carried out.

The study was approved by the Research Ethics Committee (REC), under Certificate of Presentation for Ethical Consideration (CAAE) No. 00260026.5.0000.5330 and approval opinion No. 8.705.723.

Primary outcome: The primary outcome will be confirmed diagnosis of T2DM during the observation period, treated as a binary individual indicator. The numerator will consist of eligible individuals classified as screening-positive for T2DM according to the criteria defined in the protocol. The denominator will consist of all individuals eligible for screening on the index date of the post-intervention period. The post-intervention proportion will be compared to the historical reference value, estimated by applying the same eligibility rules and outcome definition to the historical data.

Being tested
ARISE Strategy
Keywords
Diabetes Mellitus, Type 2, Prediabetic State, Primary Health Care, Noncommunicable Chronic Diseases
Medical subject headings
Diabetes Mellitus, Type 2, Prediabetic State

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ARISE StrategyOther

    This is a pragmatic, quasi-experimental, single-arm effectiveness and implementation study using a historical comparator. The ARISE strategy will consist of two components: (1) Digital analytics layer. The layer will use structured data extracted from the e-SUS PEC (Primary Care Information System) to apply predefined eligibility rules for T2DM screening. Identified individuals will be made available in operational lists and may generate alerts for UBS managers and community health agents and technicians. The alerts will support the organization of visits, contacts, scheduling, test requests, follow-up of pending items, and patients' return to the unit. No test, consultation, diagnosis, prescription, referral, or treatment will be carried out automatically. Clinical decision-making will remain the responsibility of professionals and managers. (2) Professional training: UBS managers, community health agents, community health agent technicians, physicians, nurses, and nursing technicians

Study groups in NCT07846319
Study groupRoleWhat they receive
ARISE StrategyExperimentalNot described
Receives: Other: ARISE Strategy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proportion of individuals with confirmed diagnosis of type 2 diabetes mellitus (T2DM)

    Measured: 12 months post-intervention (compared to a 12-month historical reference period)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Sep 2026
  2. Study startNov 2026 (estimated)
  3. Primary completionNov 2027 (estimated)
  4. Study completionNov 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Model description
This is a pragmatic, quasi-experimental, single-arm effectiveness and implementation study using a historical comparator. The ARISE strategy will consist of two components: (1) Digital analytics layer. The layer will use structured data extracted from the e-SUS PEC (Primary Care Information System) to apply predefined eligibility rules for T2DM screening. Identified individuals will be made available in operational lists and may generate alerts for UBS managers and community health agents and technicians. The alerts will support the organization of visits, contacts, scheduling, test requests, follow-up of pending items, and patients' return to the unit. No test, consultation, diagnosis, prescription, referral, or treatment will be carried out automatically. Clinical decision-making will remain the responsibility of professionals and managers. (2) Professional training: UBS managers, community health agents, community health agent technicians, physicians, nurses, and nursing technicians
Masking
None (open label)
Enrolment
45,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07846319
Sponsor's protocol ID
00260026.5.0000.5330
Acronym
ARISE
Status last verified
Oct 2026
First submitted
23 Sep 2026
Last updated
30 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing ARISE Strategy in people with Diabetes Mellitus (Type 2) and Prediabetes, run by epHealth at 2 sites in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 30 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Leonardo A Carbonera, PhD (48 936182615 ext. +55, leonardo@ephealth.com.br), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of individuals with confirmed diagnosis of type 2 diabetes mellitus (T2DM) (time frame: 12 months post-intervention (compared to a 12-month historical reference period)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in